Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal

Addiction

Volumn 113, Issue 9, 2018, Pages 1696-1705

  Hindocha, Chandni ^a   Freeman, Tom P ^a,b   Grabski, Meryem ^a,c   Stroud, Jack B ^a   Crudgington, Holly ^a   Davies, Alan C ^a   Das, Ravi K ^a   Lawn, William ^a   Morgan, Celia J A ^a,d   Curran, H Valerie ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

Abstinence; attentional bias; cannabidiol; cigarette dependence; craving; withdrawal

Indexed keywords

EID: 85047078580     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.14243     Document Type: Article

References (65)

1. World Health Organisation. WHO global report on trends in prevalence of tobacco smoking 2015. Geneva, Switzerland: WHO Press; 2015
2. Grabski M., Curran H. V., Nutt D. J., Husbands S. M., Freeman T. P., Fluharty M. et al. Behavioral tasks sensitive to acute abstinence and predictive of smoking cessation success: a systematic review and meta-analysis. Addiction 2016; 111: 2134–2144
3. Hughes J. R. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 2007; 9: 315–327
4. Killen J. D., Fortmann S. P. Craving is associated with smoking relapse: findings from three prospective studies. Exp Clin Psychopharmacol 1997; 5: 137–142
5. Piasecki T. M., Jorenby D. E., Smith S. S., Fiore M. C., Baker T. B. Smoking withdrawal dynamics: I. Abstinence distress in lapsers and abstainers. J Abnorm Psychol 2003; 112: 3–13
6. Patterson F., Jepson C., Loughead J., Perkins K., Strasser A. A., Siegel S. et al. Working memory deficits predict short-term smoking resumption following brief abstinence. Drug Alcohol Depend 2010; 106: 61–64
7. Potenza Marc N., Sofuoglu M., Carroll Kathleen M., Rounsaville Bruce J. Neuroscience of behavioral and pharmacological treatments for addictions. Neuron 2011; 69: 695–712
8. Schnoll R. A., Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs 2006; 11: 429–444
9. Cahill K., Lindson-Hawley N., Thomas K. H., Fanshawe T. R., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2016; Issue 5 Art. No.: CD006103. https://doi.org/10.1002/14651858.CD006103.pub7
10. Parsons L. H., Hurd Y. L. Endocannabinoid signalling in reward and addiction. Nat Rev Neurosci 2015; 16: 579–594
11. Lawn W., Freeman T. P., Pope R. A., Joye A., Harvey L., Hindocha C. et al. Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypothese. Psychopharmacology (Berl) 2016; 233: 3537–3552
12. Zlebnik N. E., Cheer J. F. Beyond the CB1 receptor: is cannabidiol the answer for disorders of motivation? Annu Rev Neurosci 2016; 39: 1–17
13. Prud'homme M., Cata R., Jutras-Aswad D. Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Subst Abuse Res Treat 2015; 9: 33–38
14. Hindocha C., Lawn W., Freeman T. P., Curran H. V. Individual and combined effects of cannabis and tobacco on drug reward processing in non-dependent users. Psychopharmacology (Berl) 2017; 234: 3153–3163
15. Viudez-Martínez A., García-Gutiérrez M. S., Navarrón C. M., Morales-Calero M. I., Navarrete F., Torres-Suárez A. I. et al. Cannabidiol reduces ethanol consumption, motivation and relapse in mice. Addict Biol 2018; 23: 154–164
16. Le Foll B., Goldberg S. R. Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 2004; 15: 2139–2143
17. Forget B., Hamon M., Thiébot M.-H. Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology (Berl) 2005; 181: 722–734
18. Cahill K., Ussher M. H. Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database Syst Rev 2011; Issue 3 Art. No.: CD005353. https://doi.org/10.1002/14651858.CD005353.pub4
19. Robinson J. D., Cinciripini P. M., Karam-Hage M., Aubin H. J., Dale L. C., Niaura R. et al. Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation. Addict Biol 2017; 23: 291–303
20. Pertwee R. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153: 199–215
21. Russo E. B. Beyond cannabis: plants and the endocannabinoid system. Trends Pharmacol Sci 2016; 37: 594–605
22. Hindocha C., Freeman T. P., Schafer G., Gardener C., Das R. K., Morgan C. J. et al. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur Neuropsychopharmacol 2015; 25: 325–334
23. Babalonis S., Haney M., Malcolm R. J., Lofwall M. R., Votaw V. R., Sparenborg S. et al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 2016; 172: 9–13
24. Haney M., Malcolm R. J., Babalonis S., Nuzzo P. A., Cooper Z. D., Bedi G. et al. Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis. Neuropsychopharmacology 2015; 41: 1974–1982
25. Fusar-Poli P., Crippa J. A., Bhattacharyya S., Borgwardt S. J., Allen P., Martin-Santos R. et al. Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009; 66: 95–105
26. Bergamaschi M. M., Queiroz R. H. C., Chagas M. H. N., de Oliveira D. C. G., De Martinis B. S., Kapczinski F. et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology 2011; 36: 1219–1226
27. Hughes J. R. Tobacco withdrawal in self-quitters. J Consult Clin Psychol 1992; 60: 689–697
28. Morgan C. J., Das R. K., Joye A., Curran H. V., Kamboj S. K. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 2013; 38: 2433–2436
29. Morgan C. J., Freeman T. P., Schafer G. L., Curran H. V. Cannabidiol attenuates the appetitive effects of Δ9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 2010; 35: 1879–1885
30. Waters A. J., Shiffman S., Sayette M. A., Paty J. A., Gwaltney C. J., Balabanis M. H. Attentional bias predicts outcome in smoking cessation. Health Psychol 2003; 22: 378–387
31. Franken I. H. Drug craving and addiction: integrating psychological and neuropsychopharmacological approaches. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 563–579
32. Freeman T., Morgan C., Beesley T., Curran H. Drug cue induced overshadowing: selective disruption of natural reward processing by cigarette cues amongst abstinent but not satiated smokers. Psychol Med 2012; 42: 161–171
33. Ren Y., Whittard J., Higuera-Matas A., Morris C. V., Hurd Y. L. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci 2009; 29: 14764–14769
34. Hurd Y. L., Yoon M., Manini A. F., Hernandez S., Olmedo R., Ostman M. et al. Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics 2015; 12: 807–815
35. Bhattacharyya S., Falkenberg I., Martin-Santos R., Atakan Z., Crippa J. A., Giampietro V. et al. Cannabinoid modulation of functional connectivity within regions processing attentional salience. Neuropsychopharmacology 2015; 40: 1343–1352
36. Lerman C., LeSage M. G., Perkins K. A., O'Malley S. S., Siegel S. J., Benowitz N. L. et al. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 2007; 6: 746–762
37. Benowitz N. L., Jacob P. III, Ahijevych K., Jarvis M. J., Hall S., LeHouezec J. et al. Biochemical verification of tobacco use and cessation. Nicotine Tob Res 2002; 4: 149–159
38. Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerstrom K. O. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 1119–1127
39. Button K. S., Ioannidis J. P., Mokrysz C., Nosek B. A., Flint J., Robinson E. S. et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 2013; 14: 365–376
40. Leweke F., Piomelli D., Pahlisch F., Muhl D., Gerth C., Hoyer C. et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012; 2: e94
41. Charles M., Wellington C., Mokrysz C., Freeman T., O'Ryan D., Curran H. Attentional bias and treatment adherence in substitute-prescribed opiate users. Addict Behav 2015; 46: 100–105
42. Mogg K., Bradley B. P., Field M., De Houwer J. Eye movements to smoking-related pictures in smokers: relationship between attentional biases and implicit and explicit measures of stimulus valence. Addiction 2003; 98: 825–836
43. Peirce J. W. PsychoPy—psychophysics software in Python. J Neurosci Methods 2007; 162: 8–13
44. Peirce J. W. Generating stimuli for neuroscience using PsychoPy. Front Neuroinform 2009; 2: 10
45. West R., Hajek P. Evaluation of the mood and physical symptoms scale (MPSS) to assess cigarette withdrawal. Psychopharmacology (Berl) 2004; 177: 195–199
46. Tiffany S. T., Drobes D. J. The development and initial validation of a questionnaire on smoking urges. Br J Addict 1991; 86: 1467–1476
47. Spielberger C. D., Gorsuch R. L., Lushene R. E., Vagg P. R. State-trait anxiety inventory (STAI). BiB 2010; 1970: 180
48. Beck A. T., Ward C., Mendelson M. Beck Depression Inventory (BDI). Arch Gen Psychiatry 1961; 4: 561–571
49. Hindocha C., Freeman T. P., Xia J. X., Shaban N. D. C., Curran H. V. Acute memory and psychotomimetic effects of cannabis and tobacco both ‘joint’ and individually: a placebo-controlled trial. Psychol Med 2017; 47: 2708–2719
50. Baddeley A., Emslie H., Nimmo-Smith I. The Spot-the-Word test: a robust estimate of verbal intelligence based on lexical decision. Br J Clin Psychol 1993; 32: 55–65
51. Hindocha C., Freeman T. P., Grabski M., Crudgington H., Davies A. C., Stroud J. B. et al. The effects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers. Sci Rep 2018; https://doi.org/10.1038/s41598-018-25846-2
52. Mogg K., Field M., Bradley B. P. Attentional and approach biases for smoking cues in smokers: an investigation of competing theoretical views of addiction. Psychopharmacology (Berl) 2005; 180: 333–341
53. Rouder J. N., Speckman P. L., Sun D., Morey R. D., Iverson G. Bayesian t-tests for accepting and rejecting the null hypothesis. Psychon Bull Rev 2009; 16: 225–237
54. Kraemer H. A source of false findings in published research studies: adjusting for covariates. JAMA Psychiatry 2015; 72: 961–962
55. NHS-Digital. Statistics on smoking, England—2016. 2016. Available at: https://digital.nhs.uk/catalogue/PUB20781 (accessed 8 May 2018) (Archived at http://www.webcitation.org/6zfx6WpkL)
56. Field M., Cox W. M. Attentional bias in addictive behaviors: a review of its development, causes, and consequences. Drug Alcohol Depend 2008; 97: 1–20
57. Robinson T. E., Berridge K. C. Incentive-sensitization and addiction. Addiction 2001; 96: 103–114
58. Mahler S. V., Smith K. S., Berridge K. C. Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances ‘liking’ of a sweet reward. Neuropsychopharmacology 2007; 32: 2267–2278
59. Field M., Mogg K., Bradley B. P. Eye movements to smoking-related cues: effects of nicotine deprivation. Psychopharmacology (Berl) 2004; 173: 116–123
60. Justinova Z., Panlilio L. V., Moreno-Sanz G., Redhi G. H., Auber A., Secci M. E. et al. Effects of fatty acid amide hydrolase (FAAH) inhibitors in non-human primate models of nicotine reward and relapse. Neuropsychopharmacology 2015; 40: 2185–2197
61. Panlilio L. V., Justinova Z., Goldberg S. R. Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. Pharmacol Ther 2013; 138: 84–102
62. Scherma M., Panlilio L. V., Fadda P., Fattore L., Gamaleddin I., Le Foll B. et al. Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3′-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther 2008; 327: 482–490
63. Forget B., Coen K. M., Le Foll B. Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration—comparison with CB(1) receptor blockade. Psychopharmacology (Berl) 2009; 205: 613–624
64. Ataya A. F., Adams S., Mullings E., Cooper R. M., Attwood A. S., Munafo M. R. Internal reliability of measures of substance-related cognitive bias. Drug Alcohol Depend 2012; 121: 148–151
65. Zuardi A. W., Rodrigues N. P., Silva A. L., Bernardo S. A., Hallak J. E. C., Guimaraes F. S. et al. Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol 2017; 8: 259